Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03485547 · ClinicalTrials.gov registry record · Phase 1
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03485547 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants.
The verdict
NCT03485547, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax
Interventions
- DRUG Venetoclax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2025-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03485547
The ClinicalTrials.gov registry entry for NCT03485547 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Venetoclax is the first listed.
NCT03485547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03485547 about?
NCT03485547 is a clinical study titled "Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)". This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax
What is the current status of trial NCT03485547?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-08-23. Estimated completion is 2025-04-16.
What interventions are being tested in trial NCT03485547?
The interventions under investigation include: Venetoclax (DRUG).
Who is sponsoring clinical trial NCT03485547?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.